Posts by Peptra Labs Research
Tirzepatide in HFpEF: LV Mass Down 12.4 g at 6 Months
The International Journal of Cardiology published a prospective cohort study online on 8 September 2026 by Karanxha, Guni, Xhabija, Ded...
Tirzepatide 15 mg: 1.60 kg of Fat-Free Mass Lost
Tirzepatide 15 mg cut fat-free mass by 1.60 kg in a meta-analysis of 19 trials, where laboratory screening found risk the trial reports missed.
GHK-Cu: 50 Years of Research, None on Injection
GHK-Cu has decades of human trials as a topical serum and none as an injection, NPR reports, with an FDA panel reviewing the injectable in February.
Tirzepatide and Semaglutide: 15-20% in a New Review
Tirzepatide and semaglutide give 15 to 20 percent mean weight loss over 12 to 18 months, a new narrative review reports, with wider gains.
Peptides and Cancer: What Memorial Sloan Kettering Says
Peptides sold online for wellness have not been through clinical trials, and Memorial Sloan Kettering has now told patients why that matters.
Tirzepatide in Prader-Willi: 3 Measures After One Swap
Tirzepatide replaced a GLP-1 agonist in a woman with Prader-Willi syndrome and refractory diabetes, and appetite, weight and glucose all improved.
GLP-1 in Resistant Hypertension: Equal BP, 4,153 Pairs
GLP-1 agonists and mineralocorticoid antagonists cut blood pressure almost equally in 4,153 matched pairs, yet the hard outcomes separated sharply.
Tirzepatide and Metformin: When Glucose Masks Ketoacidosis
Tirzepatide with metformin preceded severe lactic acidosis and ketoacidosis at near-normal glucose in a 59-year-old woman, who recovered on dialysis.
GLP-1: WHO Guidelines, 1 Billion People, 3 Industries
GLP-1 now has a WHO guideline, and a Science editorial names the three industries competing around it: pharmaceutical, food and wellness.
Semaglutide vs Pair-Fed Rats: Splitting Drug From Weight
Semaglutide and pair-fed rats both gained on reproductive measures, but the hormone results separated the drug effect from the weight loss effect.